NCT02678078

Brief Summary

Characterization of Cancer Tissue Using 3D Biosynthetic Materials. Using liver biopsy from stage 4 cancer patients, the investigators will evaluate and characterize the metastatic cells.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2016

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

February 4, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 9, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
Last Updated

May 6, 2016

Status Verified

May 1, 2016

Enrollment Period

1.9 years

First QC Date

February 4, 2016

Last Update Submit

May 5, 2016

Conditions

Cancer

Keywords

cancerdiagnosisbiopsychemotherapy drugstumor

Outcome Measures

Primary Outcomes (1)

  • cell growth

    biopsy will be placed inside 3D gel, and growth will be measured over 1 week time.

    1 week

Interventions

Analyzing biopsy samplesPROCEDURE

Analyzing biopsy samples that is preformed as part of the patient treatment.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

every man or women 18 years old or older, with a liver tumor.

You may qualify if:

  • liver tumor

You may not qualify if:

  • refuse to volunteer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rambam

Haifa, Israel

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

we will collect a liver biopsy and blood

MeSH Terms

Conditions

NeoplasmsDisease

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Dror seliktar, Prof

    Technion, Israel Institute of Technology

    STUDY DIRECTOR

Central Study Contacts

tarek Saadi, Dr.

CONTACT

97247772947t_saadi@rambam.health.gov.il

shlomit harpaz, Msc

CONTACT

972544565257shlomith@tx.technion.ac.il

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 4, 2016

First Posted

February 9, 2016

Study Start

February 1, 2016

Primary Completion

January 1, 2018

Study Completion

January 1, 2018

Last Updated

May 6, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will share

Locations

IL(1)